시장보고서
상품코드
1480807

세계의 HER2 항체 시장

HER2 Antibodies

발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 197 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

HER2 항체 세계 시장은 2030년까지 282억 달러에 이를 전망

2023년에 172억 달러로 추정된 HER2 항체 세계 시장은 2023-2030년의 분석 기간 중에 CAGR 7.3%로 성장하여 2030년에는 282억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Trastuzumab은 CAGR 7.7%를 나타내고, 분석 기간 종료시에는 185억 달러에 이를 것으로 예상됩니다. Lapatinib 부문의 성장은 향후 7년간 CAGR이 7.1%로 추정됩니다.

미국 시장은 52억 달러로 추정, 중국은 CAGR 6.6%로 성장할 것으로 예측

미국의 HER2 항체 시장은 2023년에는 52억 달러에 이를 것으로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 48억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2023-2030년간 연평균 복합 성장률(CAGR)은 6.6%입니다. 기타 주목해야 할 지역 시장으로서 일본과 캐나다가 있으며, 각각 2023-2030년간 6.4%와 6.1%의 성장이 예측됩니다. 유럽에서는 독일이 CAGR 약 5.5%로 성장할 것으로 예측됩니다.

2024년 매력적인 새로운 보고서 기능 소개

인플루언서 참여 통계에 풀 액세스

디지털 아카이브와 'MarketGlass' 리서치 플랫폼에 무료로 액세스하세요. 당사의 독자적인 MarketGlass 플랫폼은 전 세계 전문가들의 창의성과 시장 지식을 통합적이고 협력적으로 발휘할 수 있도록 지원합니다. 당사의 최첨단 툴은 시장 진출기업의 프라이버시와 신원을 보호하면서 세계적 수준의 시장 관점을 제공합니다. 이 보고서의 수치, 통계 및 시장 설명은 해당 분야의 전문가와 인플루언서들이 공유한 엄선된 인사이트를 기반으로 합니다.

실시간 데이터 시뮬레이터 툴이나 맞춤형 보고서 작성 기능을 갖춘 인터랙티브인 설문조사에 참가할 수 있습니다.

기업 간의 스마트한 의견 교환을 위한 동료 협업 및 대화형 플랫폼에 대한 전체 클라이언트 액세스 권한 부여

1년간 무료 보고서 업데이트

주요 기업 - 세계 시장 점유율을 포함한 경쟁 커버리지

여러 지역에서 기업의 시장 포지셔닝 분석(호조/활발/니치/마이너)

전문가/기업 인터뷰, 팟캐스트, 프레스 발표, 이벤트 기조 강연 YouTube 비디오 액세스

2024년 세계 경제에 기대하는 것

금융긴축과 그에 따른 금리 상승에 의해 발생하는 지정학적/경제적 불안정성이 2024년 격동 상황을 만들어 낼 것으로 예상됩니다. 중동의 적대 행위와 점점 더 빈번해지는 기후 재난 등여러 요인이 복구의 길에 계속 압력을 가할 것입니다. 이러한 리스크 가운데 디스인플레이션의 조짐과 고질적인 인플레이션에 대한 불안감 완화, 공급망 정상화, 에너지 비용의 변동성에도 불구하고 가격 조정 등 몇 가지 긍정적인 요소도 구체화되고 있습니다. 인도나 미국을 비롯한 G21 국가 선거는 자본 흐름이나 투자 전략에 영향을 미치는 가능성이 있습니다. 인도가 글로벌 투자 환경에서 매력적인 투자처로 부상하고 있지만, 미국에 기반을 둔 기술 기업들은 역동적인 인재와 자본 생태계에 힘입어 계속해서 우위를 점할 것입니다. 실리콘밸리와 그 밖의 지역의 기술 기회는 둔화되기는 했지만 회복세를 보이고 있는 국내 경제와 우호적인 규제 환경에 힘입어 고성장 전망을 추구하는 투자자들에게 여전히 매력적입니다. 유럽은 금융긴축정책과 경기후퇴 리스크와의 싸움이 계속 되지만, 영국은 전망이 가장 어렵고, 2024년 경기후퇴 리스크가 가장 높습니다. 중국은 정부 지출과 소비자 지출의 개선에 힘입어 성장에 대한 희망을 품고 있는 와일드카드로 남아 있습니다. 변동성이 큰 환경은 투자자와 기업 모두에게 기회와 도전을 동시에 제공할 것입니다. 투자 결정을 내릴 때 민첩성과 전략적 선견지명과 함께 변동성을 성장의 촉매제로 받아들이는 것이 생존을 위해 여전히 중요할 것입니다.

조사 대상 기업 예(총 47개사)

  • Abnova Corporation
  • Biocon Ltd.
  • Bio-Techne Coporation
  • Celltrion, Inc.
  • Genentech, Inc.
  • Invivogen
  • Novartis AG
  • Pfizer, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 세계 기타 지역

제4장 경쟁

LSH 24.06.03

Global HER2 Antibodies Market to Reach $28.2 Billion by 2030

The global market for HER2 Antibodies estimated at US$17.2 Billion in the year 2023, is expected to reach US$28.2 Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2023-2030. Trastuzumab, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$18.5 Billion by the end of the analysis period. Growth in the Lapatinib segment is estimated at 7.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $5.2 Billion, While China is Forecast to Grow at 6.6% CAGR

The HER2 Antibodies market in the U.S. is estimated at US$5.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.4% and 6.1% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 47 Featured) -

  • Abnova Corporation
  • Biocon Ltd.
  • Bio-Techne Coporation
  • Celltrion, Inc.
  • Genentech, Inc.
  • Invivogen
  • Novartis AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • HER2 Antibodies - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for HER2 Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for HER2 Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for HER2 Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Trastuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Trastuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Trastuzumab by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Lapatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Lapatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Lapatinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Ado-trastuzumab emtansine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Ado-trastuzumab emtansine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Ado-trastuzumab emtansine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Pertuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Pertuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Pertuzumab by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Everolimus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Everolimus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Everolimus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World HER2 Antibodies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2024 & 2030
  • JAPAN
    • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2024 & 2030
  • CHINA
    • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2024 & 2030
  • EUROPE
    • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for HER2 Antibodies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for HER2 Antibodies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for HER2 Antibodies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2024 & 2030
  • FRANCE
    • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2024 & 2030
  • GERMANY
    • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • HER2 Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 56: Rest of World Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of World Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of World 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제